ai for pharmaceutical
How pharma and life sciences companies use AI for regulatory writing, medical affairs content, clinical documentation, and HCP communication. Real use cases.
What to Keep Human
Scientific and clinical judgment must remain with qualified professionals. AI does not make clinical decisions, determine safety signals, or interpret ambiguous data with clinical implications. All AI-generated medical content requires review by qualified medical affairs professionals, and all regulatory submissions require the signature of qualified regulatory affairs professionals who stand behind their accuracy.
In a regulated industry, the expert review obligation isn't a formality — it's a professional and legal responsibility that cannot be delegated to AI.
ROI for Pharma and Life Sciences Operations
Life sciences companies that implement AI documentation tools in medical affairs and regulatory operations typically see document production timelines compress by 20 to 40 percent. Medical writers and regulatory affairs professionals spend more time on complex judgment work and less time on initial drafting. Field team training materials are more current and consistent when AI supports the production cycle.
Compliance and Regulatory Considerations
All AI-generated content in pharmaceutical and life sciences operations is subject to the same quality systems, review requirements, and document control standards as human-generated content. GxP compliance applies to AI-assisted content used in regulated activities. FDA's emerging guidance on AI in drug development and manufacturing is evolving rapidly — regulatory affairs teams should monitor and incorporate applicable guidance. Data integrity requirements apply to AI systems that interact with clinical or quality data.
What Implementation Looks Like
Pharma AI projects require more extensive compliance review upfront than most industries. The engagement includes an assessment of applicable regulatory requirements, a review of your quality system requirements for AI-assisted content, and pilot testing in a controlled environment before production deployment. Implementation timelines are typically six to twelve weeks, including the quality system integration steps.
Running Start Digital works with pharmaceutical and life sciences companies on AI implementations that comply with GxP requirements and produce output that meets the quality standards of regulated environments.
Frequently Asked Questions
Q: Does using AI for regulatory documents require FDA notification or validation?
A: FDA guidance on AI use in drug development and manufacturing is evolving. Currently, AI-assisted writing tools are generally treated as writing aids rather than computerized systems requiring CSV validation — but this depends on the specific use case and how the AI is used. Any AI system that makes or influences regulatory decisions rather than assisting with document drafting requires more careful regulatory analysis. Your regulatory affairs team should evaluate specific use cases against current guidance and your quality system requirements.
Q: How does AI handle the strict scientific accuracy requirements for medical content?
A: AI generates content from the information provided to it. For medical affairs content, this means AI must be provided with approved, accurate source data: clinical study reports, label language, published literature. The AI organizes and drafts from this material; the medical affairs professional verifies accuracy and clinical appropriateness. AI that is given inaccurate or unapproved source material will generate inaccurate content — the quality of inputs determines the quality of outputs.
Q: Can AI assist with adverse event report writing while maintaining data integrity?
A: AI can assist with adverse event documentation by generating structured report drafts from case data, reducing the time pharmacovigilance staff spend on initial documentation. All AI-generated PV documentation requires expert review and approval before submission. Data integrity requirements apply: the AI-assisted process must include audit trails and quality control steps that meet your quality system requirements.
Q: What are the confidentiality considerations when using AI with clinical trial data?
A: Clinical trial data is among the most sensitive information a life sciences company handles: patient data subject to HIPAA, proprietary efficacy and safety data, and pre-submission regulatory data. AI systems used with clinical data must have appropriate security controls, data isolation, and contractual data handling guarantees. Consumer AI tools and general-purpose cloud services are not appropriate for clinical trial data. Enterprise deployments with validated, secure environments are required.
Ready to put this into action?
We help businesses implement the strategies in these guides. Talk to our team.